share_log

開拓藥業-B：自願公告 - KX-826與米諾地爾聯合治療男性AGA的臨床試驗獲NMPA批准

KINTOR PHARMA-B: VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL OF KX-826 AND MINOXIDIL COMBINATION THERAPY FOR THE TREATMENT OF MALE AGA RECEIVED CLEARANCE BY CHINA NMPA

香港交易所 ·  Feb 1 03:46
Summary by Moomoo AI
開拓藥業-B宣布其自主研發的KX-826與米諾地爾聯合治療中國成年男性雄激素性脫髮（AGA）的Ib/III期臨床試驗已獲國家藥品監督管理局（NMPA）批准。該臨床試驗旨在評價聯合治療方案對於AGA患者的有效性及安全性。KX-826是開拓藥業的核心藥物，已在中國和美國完成多項臨床試驗，展現出良好的安全性和有效性。米諾地爾自1988年起被美國FDA批准用於治療脫髮。開拓藥業正進行及計劃啟動更多KX-826相關的臨床試驗，以探索其在皮膚科領域的潛在治療效果。公司提醒股東及潛在投資者，開發和銷售KX-826的成功尚無法確定，買賣股份需謹慎。
開拓藥業-B宣布其自主研發的KX-826與米諾地爾聯合治療中國成年男性雄激素性脫髮（AGA）的Ib/III期臨床試驗已獲國家藥品監督管理局（NMPA）批准。該臨床試驗旨在評價聯合治療方案對於AGA患者的有效性及安全性。KX-826是開拓藥業的核心藥物，已在中國和美國完成多項臨床試驗，展現出良好的安全性和有效性。米諾地爾自1988年起被美國FDA批准用於治療脫髮。開拓藥業正進行及計劃啟動更多KX-826相關的臨床試驗，以探索其在皮膚科領域的潛在治療效果。公司提醒股東及潛在投資者，開發和銷售KX-826的成功尚無法確定，買賣股份需謹慎。
Breakthrough Pharma-B announces its independently developed Phase Ib/III clinical trial of KX-826 with Minodyl for the joint treatment of Chinese adult male androgenic alopecia (AGA) has been approved by the National Drug Administration (NMPA). The clinical trial was designed to evaluate the efficacy and safety of the combination therapy in patients with AGA. KX-826 is a pioneering pharmaceutical drug that has completed multiple clinical trials in China and the United States and has demonstrated good safety and efficacy. Minodyl has been approved by the US FDA since 1988 to treat hair loss. Breakthrough Pharmaceuticals is underway and plans to launch more clinical trials related to KX-826 to explore its potential therapeutic effects in the field of dermatology. The Company reminds shareholders and potential investors that the success of the KX-826 development and sale of the KX-826 is not yet certain, and caution should be exercised when buying and selling shares.
Breakthrough Pharma-B announces its independently developed Phase Ib/III clinical trial of KX-826 with Minodyl for the joint treatment of Chinese adult male androgenic alopecia (AGA) has been approved by the National Drug Administration (NMPA). The clinical trial was designed to evaluate the efficacy and safety of the combination therapy in patients with AGA. KX-826 is a pioneering pharmaceutical drug that has completed multiple clinical trials in China and the United States and has demonstrated good safety and efficacy. Minodyl has been approved by the US FDA since 1988 to treat hair loss. Breakthrough Pharmaceuticals is underway and plans to launch more clinical trials related to KX-826 to explore its potential therapeutic effects in the field of dermatology. The Company reminds shareholders and potential investors that the success of the KX-826 development and sale of the KX-826 is not yet certain, and caution should be exercised when buying and selling shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more